Scientists have developed a promising new experimental treatment that could one day help men with one of the most dangerous forms of prostate cancer.
The treatment is designed not only to slow the growth of tumors but also to stop cancer cells from spreading to other parts of the body. Researchers believe this double action could make it especially valuable for patients with aggressive disease, where current treatments often become less effective over time.
Prostate cancer is one of the most commonly diagnosed cancers in men. Many prostate cancers grow slowly and may never become life-threatening. However, some tumors behave very differently.
These aggressive cancers can quickly spread beyond the prostate to nearby lymph nodes and distant organs, especially the bones. Once the disease spreads, it becomes much harder to treat and greatly reduces a patient’s chances of long-term survival.
Researchers from Umeå University, together with international partners, have spent several years developing a new fully human antibody. Antibodies are proteins that can recognize and attach to specific targets in the body.
Because this antibody is made entirely from human proteins, scientists hope it may be less likely to trigger unwanted immune reactions than some older treatments.
In preclinical studies, the new antibody successfully slowed tumor growth while also preventing cancer cells from forming metastases.
Metastasis is the process in which cancer cells break away from the original tumor, travel through the blood or lymphatic system, and start new tumors elsewhere in the body. Preventing metastasis is one of the biggest goals in cancer research because it is responsible for most cancer-related deaths.
The research team also discovered how the antibody works. It blocks important biological signals that help cancer cells grow, invade nearby tissue, and spread.
Because the treatment uses a different mechanism from many existing cancer medicines, researchers believe it may also reduce the risk of some side effects while offering another option if standard therapies stop working.
The project involved close collaboration with scientists from the SciLifeLab Drug Discovery and Development Platform, who helped design and develop the antibody. Researchers now hope to investigate whether the same treatment could also work against other solid tumors, such as cancers affecting different organs.
Although the findings are exciting, the scientists stress that the work is still at an early stage. The treatment has not yet been tested in large human clinical trials. Additional safety studies and approval from regulatory agencies in Europe or the United States will be needed before doctors can prescribe it to patients.
The study was published in Signal Transduction and Targeted Therapy.
Overall, these findings are encouraging because the treatment targets both tumor growth and the spread of cancer, two major challenges in advanced prostate cancer. The study was carried out in preclinical models, so the results do not yet prove that the drug will work safely or effectively in people.
More laboratory testing, human clinical trials, and approval from health regulators will be required before patients can receive the treatment. Even so, the research represents an important early step toward developing a new type of targeted cancer therapy that may improve survival and quality of life for people with aggressive prostate cancer.
If you care about prostate cancer, please read studies about 5 types of bacteria linked to aggressive prostate cancer, and new strategy to treat advanced prostate cancer.
For more information about prostate cancer, please see recent studies about new way to lower risk of prostate cancer spread, and results showing three-drug combo boosts survival in metastatic prostate cancer.
Source: Umeå University.
